Healthy
Conditions
Keywords
relative bioavailability, food-effect
Brief summary
This study will be an open-label, randomized, single dose, 3-period crossover PK study. This study will comprise 3 treatment periods with a 4-day washout between periods. On Day -1, subjects will be randomized to 1 of 6 treatment sequences. On Days 1, 5, and 9, subjects will be administered Treatment A, B, or C according to the randomization schedule. * Treatment A: a single dose of 160 mg ACY-1215 CLF (20 mg/mL) in the fed state * Treatment B: a single dose of 120 mg ACY-1215 ALF (10 mg/mL) in the fed state * Treatment C: a single dose of 120 mg ACY-1215 ALF (10 mg/mL) in the fasted state
Detailed description
Subjects will be confined to the Clinical Research Unit (CRU) from the time of Check-in (Day -1) to Day 10. Predose blood and urine samples will be obtained prior to each ACY-1215 administration. Following administration of ACY-1215 in each period, blood and urine samples will be collected at specified timepoints or intervals through 24 hours postdose for the determination of the PK of a single oral dose of ACY-1215. Subjects will be discharged from the CRU on Day 10, following the completion of the last PK collection and successful completion and evaluation of discharge safety tests. Subjects will return to the clinic for a Follow-up visit 5 to 7 days after the last dose of ACY-1215 (Days 14 to 16) for additional safety evaluations.
Interventions
DRUGACY-1215
Sponsors
Acetylon Pharmaceuticals Incorporated
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* 18 to 65 years of age, inclusive * BMI range 18.5 to 32.0 kg/m2 * in good health, as determined by no clinically significant findings from medical history, 12-lead ECG, vital signs * clinical laboratory evaluations, CBC, coagulation, and UA * negative test for selected drugs of abuse * negative hepatitis panel and negative HIV antibody * females of non-childbearing potential as outlined in protocol * males either be sterile or agree to use contraception as outlined in protocol
Exclusion criteria
* significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder * history of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance * history of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs * history of Gilbert's Syndrome or suspicion of Gilbert's Syndrome * abnormality in the 12-lead ECG (e.g. QTcF of \>450 msec, a history of a prolonged QTc-interval or Brugada syndrome) * history of alcoholism or drug addiction within 1 year prior * participation in any other investigational study drug trial in which receipt of an investigational study drug as outlined in protocol * use of any prescription medications/products within 14 days (30 days for cytochrome P450 \[CYP\]-inducing or inhibiting products as outlined in protocol) * use of any over-the-counter, nonprescription preparations within 14 days * use of any tobacco or nicotine-containing products within 6 months and during study; * poor peripheral venous access * donation of blood from 30 days prior to Screening through the Follow-up visit * any acute or chronic condition that, in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in this clinical study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area Under the Curve From Zero to Last Time - AUC0-last | 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12 and 24 hr post first dose |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety and tolerability parameters | Day 1 (first dose of ACY-1215) to Day 16 | Changes from baseline in clinical laboratory assessments, vital signs, electrocardiogram values, and physical exam. This includes collection of adverse events and the collection of concomitant medications. |
| Area Under the Curve From Time Zero to Extrapolated Infinite Time | 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12 and 24 hr post first dose | — |
| Maximum Observed Plasma Concentration (Cmax) | 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12 and 24 hr post first dose | — |
| Plasma Decay Half-Life | 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12 and 24 hr post first dose | — |
Countries
United States
Outcome results
None listed